Frontline and relapsed treatment of follicular lymphoma

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Jeremy S. Abramson, MD, of the Massachusetts General Hospital Cancer Center, Boston, MA, discusses advances in the treatment of patients with follicular lymphoma. In the relapsed setting, novel therapeutic agents include the phosphoinositide 3-kinase inhibitors, idelalisib and duvelisib; the immunomodulatory agent, lenalidomide; the anti-CD20 monoclonal antibody, obinutuzumab; the Bcl-2 inhibitor, venetoclax; and antibody-drug conjugates. In the frontline setting, novel therapeutic approaches include a combination of lenalidomide and the anti-CD20 monoclonal antibody, rituximab.